New Antibody-Drug conjugate takes aim at Hard-to-Treat prostate cancer
Disease control
Recruiting now
This study tests a new drug called TD001 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. TD001 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to prostate cancer cells that have a specific marker (…
Phase: PHASE1, PHASE2 • Sponsor: T.O.A.D. Oncology SA • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC